Literature DB >> 14498981

Antigenic variations in the CD4 induced sites of the CCR5-tropic, pathogenic SHIVsf162p3 gp120 variants.

M Hsu1, C Buckner, J Harouse, A Gettie, J Blanchard, J E Robinson, C Cheng-Mayer.   

Abstract

In vivo passage of non-pathogenic, CCR5-tropic simian/human immunodeficiency virus (SHIV) - SHIVsf162 resulted in a pathogenic isolate, SHIVsf162p3. In an attempt to characterize envelope (Env)-mediated properties that may contribute to its pathogenicity, major (P3 major) and minor (P3 minor) Env gp120 variants were cloned from the plasma of a SHIVsf162p3-infected animal, and expressed in the context of luciferase reporter viruses. Entry mediated by these envelopes and susceptibility to neutralization by CD4 induced-site (CD4i) antibodies (MAbs) was analyzed in comparison to parental SF162. Sequence analysis revealed that the P3 major and minor variant Envs contained 14 and 17 amino acid changes, respectively, compared with SF162. The rank order of entry mediated by the three envelopes was P3 major > SF162 > P3 minor, whereas the reverse order was observed for susceptibility to neutralization by CD4i MAbs. Since CD4i epitopes overlap the coreceptor (CoR) binding site, these findings suggest that the amino acid changes accumulated upon in vivo passage of SHIVsf162 result in Env gp120 structural rearrangements that modulate the exposure and/or conformation of the CoR binding site. This, in turn, led to increased entry and infectivity of the P3 major variant and may be responsible, in part, for the enhanced pathogenicity of SHIVsf162p3.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14498981     DOI: 10.1034/j.1600-0684.2003.00027.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  9 in total

1.  Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Authors:  Christopher Sundling; Sijy O'Dell; Iyadh Douagi; Mattias N Forsell; Andreas Mörner; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

2.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.

Authors:  Siu-hong Ho; Lili Shek; Agegnehu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.

Authors:  Anthony DeVico; Timothy Fouts; George K Lewis; Robert C Gallo; Karla Godfrey; Manhattan Charurat; Ilia Harris; Lindsey Galmin; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

5.  Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Stephanie J Buchl; Donna Palmer; David C Montefiori; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

6.  Cellular gene expression profiles in rhesus macaques challenged mucosally with a pathogenic R5 tropic simian human immunodeficiency virus isolate.

Authors:  Hye-kyung Chung; Cynthia A Pise-Masison; Michael F Radonovich; John Brady; Jae K Lee; Soo-Young Cheon; Phillip Markham; Anthony Cristillo; Ranajit Pal
Journal:  Viral Immunol       Date:  2008-12       Impact factor: 2.257

7.  Repressive effect of primary virus replication on superinfection correlated with gut-derived central memory CD4(+) T cells in SHIV-infected Chinese rhesus macaques.

Authors:  Jing Xue; Zhe Cong; Jing Xiong; Wei Wang; Hong Jiang; Ting Chen; Fangxin Wu; Kejian Liu; Aihua Su; Bin Ju; Zhiwei Chen; Marcelo A Couto; Qiang Wei; Chuan Qin
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

8.  In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.

Authors:  David Davis; Wim Koornstra; Zahra Fagrouch; Ernst J Verschoor; Jonathan L Heeney; Willy M J M Bogers
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

9.  Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Guojun Yang; Stephanie J Buchl; Patrick W Hanley; Donna Palmer; David C Montefiori; Guido Ferrari; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.